爵士製藥 JAZZ 深 滬
等待開盤 03-26 09:30:00 美东时间
189.08
+4.070
+2.20%
華盛通- 最 高189.40
- 今 開186.71
- 成交量 83.29万股
- 最 低 186.00
- 昨 收 185.01
- 總市值 116.40亿
- 52周最高 198.00
- 市盈率 靜 --
- 換手率 1.35%
- 52周最低 95.49
- 委 比 -89.69%
- 總股本 6156.04万
- 歷史最高 198.00
- 量 比 0.92
- 振 幅 1.84%
- 歷史最低 31.87
- 每 手 1
- 風險率 27.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME) announced that its management will participate in two upcoming investor conferences. On April 15, they will present at the Needham 25th Annual Virtual Healthcare Conference at 10:15 am ET. On April 21, they will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Zymeworks, a global biotechnology company, focuses on developing multifunctional biotherapeutics for various diseases,...
03-24 10:00
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
U.S. RESEARCH ROUNDUP- Carnival, Five Below, McKesson
U.S. RESEARCH ROUNDUP- Carnival, Five Below, McKesson March 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carnival, Five Below and McKesson, on Thursday. HIGHLIGHTS * Carnival Corp CCL.N : Morgan Stanley raises to o
03-19 14:52
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
ZYME announced that new clinical and preclinical data for its ADC candidates ZW191, ZW437, and ZW418 will be presented at the AACR meeting in April 2026. ZW191, a folate receptor alpha-targeting ADC, shows strong anti-tumor activity when combined with standard-of-care agents. New candidates from the novel pan-RAS inhibitor ADC platform demonstrate potent activity across RAS-mutated cancers. The company also shared updates on its mRNA translation ...
03-17 21:02
Day One Biopharma to be acquired by Servier for $2.5B
U.S. cancer drug developer Day One Biopharmaceuticals (DAWN) has agreed to be acquired by French pharmaceutical group Servier in an all-cash deal worth nearly $2.5B, according to a statement from the ...
03-06 22:07
Day One Biopharmaceuticals gains amid takeover speculation
Day One Biopharmaceuticals (DAWN) jumped 17% amid some takeover speculation. There's speculation that Ipsen (IPSEY) and Jazz Pharmaceuticals (JAZZ) are interested in a takeover of Day One (DAWN), acco...
03-05 02:04
Zymeworks Secures $250 Million Royalty-Backed Note Financing From Royalty Pharma
Zymeworks Secures $250 Million Royalty-Backed Note Financing From Royalty Pharma Zymeworks Inc. has entered a $250 million non-recourse royalty-backed note financing with Royalty Pharma. Repayment will come from 30% of Zymeworks’ worldwide tiered royalties on Ziihera owed by partners Jazz Pharmaceut
03-02 19:01
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
